secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001213900-24-010267
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics prices $50M underwritten offering of 3.9M shares at $12.95/share
--------------------------------------------------------------------------------

- Gross proceeds ~$50M from 3,900,000 shares of common stock at $12.95 per share.
- Net proceeds to fund clinical development of briquilimab in mast-cell diseases (CSU, CIndU) and general corporate purposes.
- Offering expected to close on or about Feb 8, 2024; underwriters include TD Cowen and Evercore ISI.
- Directors and executive officers subject to 90-day lock-up expiring May 7, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024010267/0001213900-24-010267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024010267/ea192943-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-010267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer